CD28 and neoplasm: Immune checkpoint inhibitors targeting the B7-CD28 family members have shown clinically relevant efficacy in a number of tumor types and have revolutionized the strategy in cancer treatment (Mahoney et al., 2015; Picarda et al., 2016; Ramagopal et al., 2017).